BMO Capital Initiates Coverage on SAGE Therapeutics Inc(NASDAQ:SAGE). The shares have been rated Outperform. The rating by BMO Capital was issued on Jun 29, 2016.
In a different note, H.C. Wainwright said it Initiates Coverage on SAGE Therapeutics Inc, according to a research note issued on Jun 23, 2016. The shares have been rated ‘Buy’ by the firm. Chardan Capital said it Initiates Coverage on SAGE Therapeutics Inc, according to a research note issued on May 24, 2016. The shares have been rated ‘Sell’ by the firm. Chardan Capital said it Initiates Coverage on SAGE Therapeutics Inc, according to a research note issued on May 24, 2016. The shares have been rated ‘Sell’ by the firm.
SAGE Therapeutics Inc (SAGE) made into the market gainers list on Fridays trading session with the shares advancing 3.22% or 0.97 points. Due to strong positive momentum, the stock ended at $31.1, which is also near the day’s high of $31.47. The stock began the session at $30.05 and the volume stood at 4,69,912 shares. The 52-week high of the shares is $77.48 and the 52 week low is $26.2801. The company has a current market capitalization of $997 M and it has 3,20,63,547 shares in outstanding.
SAGE Therapeutics Inc(SAGE) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.97. Analysts had estimated an EPS of $-0.98.
Several Insider Transactions has been reported to the SEC. On May 18, 2016, Kevin P Starr (director 10% owner) sold 850,000 shares at $31.25 per share price.Also, On Apr 21, 2016, Stephen Kanes (Chief Medical Officer) sold 21,000 shares at $38.00 per share price.On Jan 7, 2016, Kimi Iguchi (CFO) purchased 176 shares at $49.56 per share price, according to the Form-4 filing with the securities and exchange commission.
SAGE Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.